Arrhythmia Disorders News

NEW ORLEANS — Remote monitoring of more than 32,000 patients with cardiac implantable devices during the COVID-19 pandemic reduced greenhouse gas emissions by 12,596 metric tons compared with conventional monitoring, researchers reported.

NEW ORLEANS — In patients with HF, race and ethnicity predicted the likelihood of in-hospital mortality and other outcomes after ablation for atrial fibrillation, researchers reported.

NEW ORLEANS — Elite athletes with genetic risk for sudden cardiac death can safely return to play with a shared decision-making model that includes careful evaluation, risk stratification and tailoring of genetic heart disease therapy.

NEW ORLEANS — In the PULSED AF pivotal trial, pulsed field ablation of symptomatic atrial fibrillation yielded a low rate of adverse events and demonstrated effectiveness consistent with established ablation strategies at 1 year.

Intracoronary epinephrine improved survival, return of spontaneous circulation and neurological outcomes vs. IV epinephrine for cardiac arrest during cardiac catheterization, researchers reported.

The 2023 American College of Cardiology Scientific Session will be held live in New Orleans from Saturday to Monday and virtually, with 43 late-breaking trials and featured clinical research presentations.

A next-generation left atrial appendage closure device was associated with low rates of poor outcomes and high rates of complete seal at 1 year, researchers reported at Cardiovascular Research Technologies.

Radiofrequency ablation technique was not associated with any difference in atrial fibrillation recurrence after redo ablation despite durable initial pulmonary vein isolation, researchers reported.

Eko announced the launch of a digital stethoscope that includes the use of artificial intelligence to identify structural heart murmurs.

In patients with atrial fibrillation, compared with usual care, early rhythm control therapy reduced risk for poor outcomes in both sexes, according to new data from the EAST-AFNET 4 trial.